Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.

Erlinge D, James S, Deanfield J, Eriksson N, de Belder M, Alchay M, Austin D, Jones DA, Ravn-Fischer A, Sederholm Lawesson S, Shah N, Strange JW, Szummer K, Ridderstråle W, Parvaresh Rizi E, Langkilde AM, Johansson PA, McGuire DK, Oldgren J, Storey RF

Open source

DOI: 10.1002/ehf2.15420
Published: 2025 Dec
Container: ESC heart failure
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ehf2.15420,
  title = {Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.},
  author = {Erlinge D and James S and Deanfield J and Eriksson N and de Belder M and Alchay M and Austin D and Jones DA and Ravn-Fischer A and Sederholm Lawesson S and Shah N and Strange JW and Szummer K and Ridderstråle W and Parvaresh Rizi E and Langkilde AM and Johansson PA and McGuire DK and Oldgren J and Storey RF},
  year = {2025},
  journal = {ESC heart failure},
  doi = {10.1002/ehf2.15420},
  url = {https://doi.org/10.1002/ehf2.15420}
}

RIS

TY  - JOUR
TI  - Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.
AU  - Erlinge D
AU  - James S
AU  - Deanfield J
AU  - Eriksson N
AU  - de Belder M
AU  - Alchay M
AU  - Austin D
AU  - Jones DA
AU  - Ravn-Fischer A
AU  - Sederholm Lawesson S
AU  - Shah N
AU  - Strange JW
AU  - Szummer K
AU  - Ridderstråle W
AU  - Parvaresh Rizi E
AU  - Langkilde AM
AU  - Johansson PA
AU  - McGuire DK
AU  - Oldgren J
AU  - Storey RF
PY  - 2025
JO  - ESC heart failure
DO  - 10.1002/ehf2.15420
UR  - https://doi.org/10.1002/ehf2.15420
ER  -

APA

D, E., S, J., J, D., N, E., M, D. B., M, A., D, A., DA, J., A, R., S, S. L., N, S., JW, S., K, S., W, R., E, P. R., AM, L., PA, J., DK, M., J, O., & RF, S. (2025). Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.. ESC heart failure. https://doi.org/10.1002/ehf2.15420

Source records

pubmed · retrieved 2026-09-26T00:04:26.066Z